BIOMAT Database Logo BIOMAT Database Logo

Treatment of essential thrombocythaemia by alpha 2a interferon. 1988

S Bellucci, and J L Harousseau, and P Brice, and G Tobelem

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
Platelet function and interferon alpha-2a treatment in essential thrombocythaemia.
March 1991, European journal of haematology,
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
Treatment of essential thrombocythaemia by alpha-interferon.
September 1988, Lancet (London, England),
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
Recombinant alpha-2a interferon (alpha-IFN) in the treatment of essential thrombocythaemia. Preliminary report.
January 1987, Haematologica,
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.
January 1990, Leukemia & lymphoma,
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
Treatment of essential thrombocythaemia with interferon alpha-2b.
January 1989, Lancet (London, England),
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
In vitro inhibition of interferon alpha-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythaemia.
January 1992, Haematologica,
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
Recombinant interferon alpha-2b as treatment of essential thrombocythaemia.
January 1994, Acta haematologica,
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
Alpha-interferon therapy for essential thrombocythaemia.
July 1988, Lancet (London, England),
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
alpha Interferon in the management of essential thrombocythaemia.
January 1991, European journal of cancer (Oxford, England : 1990),
S Bellucci, and J L Harousseau, and P Brice, and G Tobelem
Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon.
November 1994, British journal of haematology,
Copied contents to your clipboard!